Claus Bendtsen at AstraZeneca reveals how AI can be used to improve our understanding of disease, to help identify the causes of conditions and aid in drug discovery.
List view / Grid view
Filter the results
BenevolentAI, a British artificial intelligence company, has partnered with MRC Technology (MRCT), a medical research charity, to explore drug discovery initiatives in the field of small molecules and antibodies.
BenevolentBio's CMO, Dr Patrick Keohane, says the industry is on the cusp of an artificial intelligence (AI) revolution...
BenevolentAI is the first AI company to have a CMO on its staff.
5 December 2016 | By Professor Jackie Hunter, BenevolentBio
Artificial Intelligence and machine learning present the industry with a real opportunity to do R&D differently, writes BenevolentBio's Jackie Hunter...
9 November 2016 | By Niamh Louise Marriott, Digital Content Producer
BenevolentAI, a British artificial intelligence company has signed an exclusive license for a series of novel clinical stage drug candidates with Janssen...